长期使用依那西普对幼年型特发性关节炎患儿生长的影响

原文

译文

Arthritis Rheum. 2010 Nov;62(11):3259-64. doi: 10.1002/art.27682. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Zhang N, Baumgartner SW. Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA. Edward.Giannini@cchmc.org Abstract OBJECTIVE: To evaluate the effects of long-term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA). METHODS: We conducted a 3-year, open-label, nonrandomized registry of 594 patients with polyarticular or systemic JIA treated with etanercept only, etanercept plus methotrexate, or methotrexate only. Height, weight, and body mass index (BMI) were assessed at baseline and at years 1, 2, and 3, using percentiles derived from US Centers for Disease Control and Prevention standardized growth charts. RESULTS: Statistically significant increases in the mean height percentiles from baseline were observed in etanercept-treated patients at year 3 (4.8 percentile points) and in patients treated with etanercept plus methotrexate at years 1, 2, and 3 (2.4, 3.3, and 5.6 percentile points, respectively). Statistically significant increases from baseline in the mean weight percentiles were observed at years 1, 2, and 3 in both the etanercept group (7.4, 10.0, and 13.0 percentile points) and the etanercept-plus-methotrexate group (2.9, 6.9, and 8.4 percentile points, respectively). Statistically significant increases from baseline in the mean BMI percentiles were observed in both the etanercept group (range 9.6-13.8 percentile points) and the etanercept-plus-methotrexate group (range 2.1-5.2 percentile points). The mean height, weight, and BMI percentiles did not change significantly in patients in the methotrexate-only group. CONCLUSION: Etanercept treatment, with or without methotrexate, may contribute to the restoration of normal growth in children with JIA.

长期使用依那西普对幼年型特发性关节炎患儿生长的影响 Giannini EH,et al.Arthritis Rheum. 2010 Nov;62(11):3259-64.   目的：评估长期使用依那西普（单用或联合甲氨蝶呤）对幼年型特发性关节炎（JIA）患儿生长的影响。   方法：594例多关节型或全身型JIA患儿纳入一项为期3年的开放性、非随机性登记研究，治疗分为单用依那西普、依那西普+甲氨蝶呤或单用甲氨蝶呤。在基线期和第1、2、3年评估患儿的身高、体重和体重指数（BMI），采用美国疾病控制与预防中心标准化生长图表的百分位数记录。   结果：与基线期相比，单用依那西普组在第3年（4.8百分位点）、依那西普联合甲氨蝶呤组在第1、2、3年（分别为2.4、3.3、5.6百分位点）平均身高百分位数显著上升。与基线期相比，单用依那西普组（分别为7.4、10.0、13.0百分位点）和依那西普+甲氨蝶呤组（分别为2.9、6.9、8.4百分位点）的平均体重百分位数在第1、2、3年均显著上升。与基线期相比，单用依那西普组（9.6-13.8百分位点）和依那西普+甲氨蝶呤组（2.1-5.2百分位点）的平均BMI百分位数均显著上升。单用甲氨蝶呤组的平均身高、体重和BMI均无显著变化。   结论：依那西普单用或联合甲氨蝶呤可能有助于恢复JIA患儿的正常生长。